Evidence-based guideline for the safe handling, preparation, administration, and disposal of hazardous drugs in healthcare settings, including engineering controls, PPE, and exposure management.
Evidence-based guideline for prevention, assessment, and management of oral and GI mucositis in cancer patients receiving chemotherapy, radiation, and stem cell transplantation.
Evidence-based guideline for surveillance, late effects monitoring, health promotion, and comprehensive survivorship care planning for cancer survivors.
Comprehensive, evidence-based clinical guidelines for oncology practice — synthesized from multiple professional society recommendations covering vascular access, supportive care, safety, pain management, immunotherapy, and survivorship.
The oncology department hub — ten multi-society clinical guideline series covering central venous access in cancer patients, extravasation, cancer-associated thrombosis, febrile neutropenia, CINV, mucositis, hazardous drug handling, cancer pain, immunotherapy adverse events, and survivorship.
Evidence-based guideline for recognition, grading, and management of immune-related adverse events (irAEs) across all organ systems in patients receiving checkpoint inhibitor immunotherapy.
Evidence-based guideline for risk stratification, empiric therapy, prophylaxis, and management of febrile neutropenia in cancer patients.
Evidence-based guideline for emetogenic risk classification, antiemetic regimen selection, and management of chemotherapy-induced nausea and vomiting.
Evidence-based guideline for prevention, recognition, and management of chemotherapy extravasation injuries, including agent classification, antidote protocols, and follow-up care.
Evidence-based guideline for selection, insertion, maintenance, and complication management of central venous access devices in oncology patients, synthesized from multiple professional society recommendations.
Evidence-based guideline for risk assessment, prophylaxis, diagnosis, and treatment of venous thromboembolism in cancer patients, including catheter-related thrombosis.
Evidence-based guideline for assessment, pharmacological management, interventional approaches, and supportive care of cancer-related pain.
Pediatric oncology, elderly patients, thrombocytopenic and anticoagulated patients, device removal criteria and procedures, patient and caregiver education, and quality surveillance for CVADs in oncology.
Risk-stratified survivorship care models, shared care integration, transition from oncology to primary care, pediatric and AYA survivorship, childhood cancer late effects, financial toxicity, and psychosocial support resources.
Management of immune-mediated hematologic toxicities, ophthalmologic irAEs, combination immunotherapy toxicity profiles, rechallenge criteria, preexisting autoimmune disease, special populations, multidisciplinary triggers, and patient education.
Comprehensive management of central venous access device-related thrombosis including diagnosis, treatment, catheter management decisions, upper extremity DVT, patient education, monitoring, and follow-up.
Pain management in elderly, pediatric, renal/hepatic impairment, and substance use disorder populations; non-pharmacological interventions; palliative sedation; and survivorship chronic pain strategies.
Medical surveillance program design and components, biological monitoring, reproductive health counseling and alternative duty policies, training and competency assessment requirements, documentation and record-keeping, non-antineoplastic hazardous drug considerations, home administration guidance, and quality assurance.
CLABSI prevention and treatment, catheter-associated thrombosis, occlusion management, extravasation, catheter malposition, pinch-off syndrome, and catheter damage in oncology CVAD patients.
Depression, anxiety, PTSD, fear of recurrence, sexual health, physical activity, nutrition, smoking cessation, alcohol, sun protection, and immunizations for cancer survivors.
Grade-based management of immune-mediated myocarditis, pericarditis, neurologic toxicities (myasthenia gravis, encephalitis, Guillain-Barre, neuropathy), nephritis, inflammatory arthritis, and myositis.
Empiric and targeted antifungal therapy for invasive aspergillosis and candidemia, central line-associated bloodstream infections in neutropenic patients, infection prevention measures, and patient and caregiver education.
Patient assessment and grading tools for CINV including CTCAE and MASCC Antiemesis Tool, evidence-based non-pharmacological interventions, guideline implementation strategies, quality improvement metrics, and patient education.
Management of cancer-associated VTE in special populations including brain tumors, thrombocytopenia, renal impairment, GI/GU cancers, recurrent VTE on anticoagulation, incidental and subsegmental PE, and IVC filter indications.
Adjuvant analgesic dosing for neuropathic and bone pain, interventional pain procedures, palliative radiation, and chemotherapy-induced peripheral neuropathy prevention and treatment.
Spill classification and step-by-step response procedures, spill kit contents, personnel exposure management during spills, hazardous drug waste segregation and disposal, and surface decontamination protocols including deactivation, decontamination, and cleaning agents.
Flushing and locking protocols, dressing change procedures, needleless connector management, port access and deaccess procedures, blood sampling, and patency assessment for CVADs in oncology patients.
Chemotherapy-induced diarrhea management, irinotecan-specific protocols, immune checkpoint inhibitor colitis, head and neck radiation mucositis, pelvic radiation enteritis, chemoradiation, TBI-related mucositis, palifermin in HSCT, and engraftment syndrome.
Gonadal dysfunction, fertility preservation, thyroid dysfunction, metabolic syndrome, bone health, cognitive dysfunction, cancer-related fatigue, chemotherapy-induced peripheral neuropathy, and lymphedema in cancer survivors.
Grade-based management of immune-mediated endocrine toxicities (thyroid disorders, adrenal insufficiency, hypophysitis, type 1 diabetes) and pneumonitis including workup, corticosteroid protocols, hormone replacement, and immunosuppressive escalation.
Fluoroquinolone prophylaxis, antifungal prophylaxis, antiviral and PJP prophylaxis, G-CSF primary and secondary prophylaxis with dosing and timing, therapeutic G-CSF in established febrile neutropenia, and management of persistent fever and documented infections.
Guideline-recommended antiemetic regimens by emetogenic risk level, multi-day chemotherapy protocols, oral chemotherapy CINV, radiation-induced nausea and vomiting, breakthrough and refractory CINV management, and considerations for pediatric, geriatric, and organ-impaired populations.
Surgical consultation criteria, wound grading, patient follow-up protocols, peripheral vs. central line extravasation management, documentation requirements, incident reporting, legal considerations, staff competency assessment, and institutional protocol development.
Complete treatment protocols for cancer-associated VTE including LMWH dosing, DOAC regimens (rivaroxaban, edoxaban, apixaban), warfarin considerations, duration of anticoagulation, and landmark trial data from SELECT-D, HOKUSAI-VTE Cancer, ADAM-VTE, and CARAVAGGIO.
Complete opioid pharmacotherapy for cancer pain including equianalgesic dosing, titration protocols, opioid rotation, breakthrough pain management, methadone pharmacology, and side effect treatment.
Complete PPE specifications for hazardous drug handling by activity type, including glove, gown, eye/face, and respiratory protection requirements; detailed procedures for receiving, storage, compounding, administration, patient care, and transport.
Insertion site selection, ultrasound-guided placement, tip confirmation, skin antisepsis, dressing and securement, and site care protocols for central venous access devices in oncology patients.
Evidence-based oral mucositis prevention including cryotherapy, photobiomodulation, palifermin, and basic oral care; pain management; nutritional support; infection management; agents with evidence against use.
Anthracycline cardiomyopathy, radiation-associated cardiovascular disease, cardiac monitoring protocols, cardioprotective strategies, and screening for secondary malignancies in cancer survivors.
Grade-based management of immune-mediated dermatologic toxicities (rash, pruritus, bullous pemphigoid, SJS/TEN), colitis/diarrhea, and hepatitis including workup, corticosteroid protocols, and immunosuppressive escalation.
Empiric intravenous antibiotic monotherapy and combination regimens with complete dosing, indications for vancomycin and anti-gram-positive agents, antibiotic de-escalation and duration criteria, outpatient eligibility for low-risk febrile neutropenia, oral antibiotic regimens, and monitoring requirements.
Comprehensive review of antiemetic drug classes used in CINV prophylaxis and treatment: NK1 receptor antagonists, 5-HT3 receptor antagonists, corticosteroids, olanzapine, dopamine antagonists, benzodiazepines, and cannabinoids with complete dosing, pharmacokinetics, and adverse effect profiles.
Signs and symptoms of extravasation (early and late), differential diagnosis, step-by-step immediate management algorithm, specific antidote protocols with complete dosing for dexrazoxane, hyaluronidase, sodium thiosulfate, and DMSO, and thermal management by agent class.
Evidence-based recommendations for VTE prophylaxis in ambulatory, hospitalized, and surgical cancer patients, including CVAD-related thrombosis prevention, with complete dosing tables and key trial data.
Updated WHO analgesic ladder framework, non-opioid analgesic selection and dosing, and weak opioid therapy for cancer pain management.
Hazardous drug definitions, NIOSH classification criteria, national drug list organization, exposure routes and health effects, facility risk assessment, and complete engineering control specifications including BSCs, CACIs, CSTDs, and ventilation requirements.
CVAD types and oncology-specific indications, patient assessment framework, vein selection in cancer patients, device selection algorithms, and special population considerations for central venous access in oncology.
Five-phase pathobiology model of mucositis, comprehensive grading scales (WHO, NCI CTCAE, OMAS), treatment-related and patient-related risk factors, and pre-treatment dental assessment.
Survivorship care plan components, structure, and evidence-based surveillance schedules for recurrence monitoring in breast, colorectal, prostate, lung, lymphoma, and head and neck cancer survivors.
Classes of immune checkpoint inhibitors, mechanism and epidemiology of irAEs, CTCAE grading, general management framework, corticosteroid protocols, immunosuppressive escalation, and infusion reactions.
Definitions of febrile neutropenia, MASCC risk index, CISNE score, high-risk versus low-risk classification, and comprehensive initial workup including history, physical examination, laboratory studies, blood cultures, and imaging.
Complete emetogenic risk classification of intravenous and oral chemotherapy agents (high, moderate, low, minimal), types of CINV, pathophysiology of chemotherapy-induced emesis, and patient- and treatment-related risk factors.
Complete classification of antineoplastic agents by tissue damage potential (vesicants, irritants, non-vesicants), comprehensive risk factor analysis, and evidence-based prevention strategies including vein selection, device selection, and monitoring protocols.
Pathophysiology of cancer-associated thrombosis, Virchow's triad in malignancy, and validated VTE risk assessment models including the Khorana score, Vienna CATS score, PROTECHT score, and ONKOTEV score with complete scoring tables.
Comprehensive pain assessment tools, classification systems, and cancer-specific pain syndromes for systematic evaluation of pain in oncology patients.
Clinical reference for vascular access in special populations: pediatric, NICU/neonatal, oncology, hemodialysis, critical care, geriatric, obese, and immunocompromised patients — device selection, technique modifications, and population-specific risks.
Comprehensive guide to oncology vascular access: port vs PICC decision-making, chemotherapy central access requirements, vesicant administration, CLABSI prevention in neutropenic patients, power-injectable port selection, and access management across the cancer treatment continuum.
A patient guide to chemotherapy infusion — what happens before, during, and after treatment, understanding the nadir and neutropenic precautions, managing side effects, and knowing when to seek urgent help.
Evidence-based standards for safe preparation, handling, and administration of antineoplastic medications including prescribing authorization, occupational safety and PPE requirements, closed system drug transfer devices, spill management, vesicant administration, and adverse reaction protocols.